TrialEBioMedicine2022

Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.

Jonathan A Robbins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.